Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus ...

Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed ...

Cassava Sciences (SAVA) stock falls as the company halts Alzheimer's drug program after trial failures. Read more here.

Shares of Cassava Sciences (NASDAQ: NASDAQ: SAVA) plummeted 20% as the company announced the discontinuation of its Alzheimer’s disease development program for simufilam. The decision follows the drug ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...

The Canucks and the Islanders are borderline playoff teams thanks to their head coaches Rick Tocchet and Patrick Roy.

The legislative committee mulling how to help implement Nebraska’s voter-led medical cannabis laws awaits an amendment before ...

The early racing schedule had a little hiccup again this weekend when Williams Grove had to cancel again and is planning to try yet again to get the 2025 racing season underway this Friday night at ...